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Background: The aim of this sub-study is to explore the incidence of skin rash among advanced breast cancer
(ABC) patients in a phase II trial treated with weekly nab-paclitaxel and cisplatin combination.
Methods: Nab-paclitaxel(125 mg/m2) was administered on days 1, 8, 15, followed by cisplatin(75 mg/m2) on day 1
every 28 day cycle until disease progression, intolerable toxicities or the maximum of 6 cycles. Patients who
received at least one injection of the study drug were included in this analysis of the incidence of skin rash among
Chinese patients. Toxicity was graded using the CTCAE4.0 criteria. Statistical analysis was carried out by using SPSS
16.0 (SPSS Inc, Chicago, IL).
Results: Seventy three patients were enrolled and eligible for analysis. A total of 384 cycles were administered at
the time of this analysis. Rash was presented in 27 patients (37.0%). The most common sites involved were face
(14/27), neck (14/27), limbs (18/27) and frictional parts of the trunk (10/27). Macular and papular rash with pruritus
commonly occurred 2 (95% CI: 1–7) days after the first day of chemotherapy. Only one patient developed Grade 3
skin toxicity with generalized erythroderma and disfigurement of the face requiring dose reduction. The rash
gradually regressed 2 (95% CI: 1–10) days after antihistamines used, but pigmentation remained in 13/27 cases. The
incidence rate of skin rash was significantly higher than what has been described for western patients (approximate
4%, P < 0.0001).
Conclusion: A higher rate of maculo-papular rash occurred in Chinese breast cancer patients treated with weekly
nab-paclitaxel compared to western patients. The albumin component of nab-paclitaxel might be the cause of the
skin disorder.
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Breast cancer is the most common malignancy diag-
nosed in women with more than 190,000 estimated new
cases in USA in 2009 [1]. It is estimated that 30% of
early stage patients will finally develop metastatic breast
cancer (MBC) [2]. Until now, metastatic breast cancer is
considered incurable. Although there are many trad-
itional chemotherapeutic agents for the treatment of
MBC, the best 5-year overall survival rate is only 20%
and median survival time is between 2 to 3 years [3].
The main objectives of treatment for metastatic breast
cancer are the prolongation of survival and improvement
of quality of life.
In the past decade, taxane-based regimens had played
an important role in the treatment of metastatic breast
cancer in both adjuvant and salvage setting for patients
with MBC. However, the clinical advances of taxanes
have been limited by their highly hydrophobic chemical
formulation and hypersensitivity. As a result, Abraxane,
an albumin-bound 130-nm particle form of paclitaxel,
was developed in order to avoid toxicities associated
with Cremophor (BASF Corp, Ludwigshafen, Germany),
the vehicle in solvent-based paclitaxel. Several clinical
trials [4,5] documented the improved efficacy and
favorable safety of nab-paclitaxel agent in the treatment
of MBC. The phase II trial [4] confirmed that nab-
paclitaxel administered every 3 weeks could improve the
overall response rate to 48% for all patients and 64% for
patients in first-line therapy. Time to disease progression
was 26.6 weeks and 48.1 weeks for the whole population
and those with confirmed tumor responses, respectively.
Moreover, taxane-associated toxicities were reported to
be less in frequency and severity. Another landmark
phase II trial [6] demonstrated superior efficacy of
weekly nab-paclitaxel compared with docetaxel, with a
statistically and clinically significant prolongation of
PFS (5 months) in patients receiving nab-paclitaxel
150 mg/m2 weekly compared with docetaxel 100
mg/m2 q3w. In the nab-paclitaxel 300 mg/m2 q3w regi-
men, median PFS was longer compared with docetaxel,
but the superiority did not reach statistical signifi-
cance. Therefore, weekly nab-paclitaxel was more desirable
as previously proved in solvent-based paclitaxel [7]. Several
studies exploring various polychemotherapy regimens have
demonstrated improved efficacy compared to any of these
agents as monotherapy [8,9].
As recently reported by Guan et al. [10], nab-paclitaxel
was efficient and safe for Chinese breast cancer patients
with metastastic diseases in a phase II study. However, we
noticed an interesting phenomenon that in comparison
with patients treated with sb-paclitaxol, those who treated
with nab-patients presented rash or pruritus more fre-
quently(9% vs. 27%, P < 0.05). This percentage was quite
higher than those reported in western countries [11,12].Therefore, in this study, we evaluated the efficacy
and safety of the combination of weekly nab-paclitaxel
and cisplatin in patients with advanced metastatic
breast cancer. During the enrollment period, the inci-
dence of skin rash was noted to be higher than
expected. Thus, patients who received at least one in-
jection of the study drug were included in this analysis
to determine if the incidence of skin rash is indeed
higher among Chinese patients in comparison with
western patients.Methods
This is a phase II, open-label, single-institutional study
at Shanghai Cancer Hospital, Fudan University. Females
over 18 years with histologically confirmed invasive
breast cancer who had recurrent or metastatic disease
were eligible. Patients were also required to have meas-
urable disease according to Response Evaluation Criteria
In Solid Tumors (RECIST) Criteria (version 1.1) [13],
good performance status (Eastern Cooperative Oncology
Group performance status of 0 to 1), and a life expect-
ancy longer than 12 weeks. Patients pretreated with
taxanes could be enrolled in the trial if relapsed more
than 6 months after taxanes used in neoadjuvant/adju-
vant setting, or more than 3 months in metastatic
disease who had documented responses when taxane ad-
ministered previously. Adequate organ function was re-
quired as follows: neutrophils > 2.0*109/L; platelets >
100*109/L; hemoglobin > 80 g/L; serum creatinine≤upper
limit of normal; bilirubin≤upper limit of normal; alkaline
phosphatase <5 times of upper limit of normal; ALT/
AST≤1.5 times the upper limit of the normal range
except when caused by metastatic disease.
Patients were excluded if they had clinical evidence of
active brain metastasis or clinically serious concurrent
disease, pre-existing peripheral neuropathy more than
Grade 1, concurrent hormonal or immunotherapy, or
other malignancies within the last 5 years that could
affect the diagnosis or assessment of breast cancer.
Nab-paclitaxel (125 mg/m2) was administered on days
1, 8, 15 and cisplatin (75 mg/m2) on day 1. Cycles were
repeated every 28 days with a maximum 6 cycles unless
disease progression, unacceptable toxicities, or with-
drawal of consent by patient. Treatment delay was
allowed up to a maximum 14 days if toxicities could not
be resolved to Grade 2 orless. All patients could receive
antiemetic prophylaxis per their physicians’ discretion.
Routine premedication with corticosteroid or antihista-
mines was not used. Toxicities were observed, recorded
and graded according to Common Terminology Criteria
for Adverse Events (CTC AE) 4.0 [14]. Statistical
analysis was carried out by using SPSS 16.0 (SPSS Inc,
Chicago, IL).






Tang et al. BMC Cancer 2013, 13:232 Page 3 of 6
http://www.biomedcentral.com/1471-2407/13/232This study was approved by the Ethics Committee of
Cancer Hospital, Fudan University and was registered
on www.clinicaltrials.gov (Number: NCT01149798). Our
study was conducted strictly adhering to guidelines for
the reporting of tumor marker studies (REMARK) [15].
Written informed consents for participation in the study
and image publication were obtained from participants.Premenopausal 29 39.7
Postmenopausal 44 60.3
Radical mastectomy
No previous mastectomy 5 6.8
Previous mastectomy 68 93.2
Time to first relapse, years
Median 2.55
Range 0.4-17
No. of metastatic sites
1 15 20.5
2 24 32.9




















First line 36 49.3
Second line 28 38.4
Third or more 9 12.3
Prior chemotherapy
Adjuvant/neoadjuvant (n = 68)
Anthracycline containing 53 72.6
Taxane containing 34 50.0
Both 27 39.7
Chemotherapy for MBC (n = 37)
Anthracycline containing 6 16.2
Taxane containing 12 32.4
Both 3 8.1Results
From June 2010 to October 2011, 73 patients who had
received at least one injection of the study drug were
enrolled and qualified for analysis. A total of 384 cycles
were administered. Patients characteristics are described
in Table 1.
Rash was observed in 27 patients (37.0%) among the
73 subjects since the start of their regimens, unexpect-
edly higher than what has been reported for western
patients. The most common sites noted were face (14/
27), neck (14/27), limbs (18/27) and frictional part of the
trunk such as chest, abdominal wall (10/27) and haunch
(3/27) (Figure 1). Rash was infrequently seen over the
anterior tibia area (2/27) (Figure 2).
Macular and papular rash eruption broke out with
pruritus at a median of the 2 (95% CI: 1–7) days after
the infusion of nab-paclitaxel and cisplatin. The rash
ocurred at a median of cycle 2, ranging from cycle 1 to
5. Nineteen of 73 patients suffered from Grade 1
maculopapular rash and 7 patients suffered from Grade
2 and all of those presented with pruritus. One subject
developed Grade 3 maculopapular rash, presented with
generalized erythroderma and disfigurement of the face
who needed dose-reduction for continuing the regimen.
Neither Grade 4 skin disorders nor exfoliative dermatitis
were observed in this trial.
All patients with skin rash were treated with antihista-
mines for external use until the disappearance of the
rash. The rash gradually regressed 2 (95% CI: 1–10) days
after drug use, and residual pigmentation was observed
at the site of rash in 13/27 cases, especially on the face
and neck. All of the pigmentations were classified into
Grade 1 (covering <10% BSA and no psychosocial im-
pact) as defined in CTCAE 4.0 and reached the peak at
the median time of 14 (7–50) days and then a plateau
whose regression was observed at the earliest time of
20 days after. However, there were still pigmentation
remained in 6/27 cases until the termination of this
study.
No fever or other severe allergic symptoms were ob-
served during the presence of skin rash. None of these
patients experienced any skin rash during the following
treatment cycle but pigmentation over the area persisted
in part of the patients as previous described. No signifi-
cant relationship was validated between rash and age,
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tures (P > 0.05, data not shown).Discussion
Taxanes are cell cycle-specific agents that bind with
high-affinity to microtubules, stabilizing and enhancing
tubulin polymerization and suppressing spindle micro-
tubule dynamics. However, the application of paclitaxel
has been a challenge as prophylactic antihistaminic
agents and corticosteroids are indicated for the preven-
tion of severe or even fatal reactions. Preclinical data
suggest that cremophor may also alter the pharmaco-
dynamics and free drug availability of paclitaxel [16].
Nanotechnology is a new field of interdisciplinary re-
search that has expanded rapidly and widely over the
past 10 years to help overcome problems in medicine
[17]. Nab-paclitaxel is a novel, albumin-bound, 130 nm
particle formulation of paclitaxel which is delivered in a
suspension of albumin particles, free from any kind of
solvent. It contains albumin (human), a derivative of hu-
man blood [18]. Based on effective donor screening and
product manufacturing processes, it carries an extremely
remote risk for transmission of viral diseases. However,Figure 1 Rash and pigmentaion on face (a), neck (b), limbs (c) and abalbumin of these donor may have the antigenic effects
for some patients [19]. Formulation and storage condi-
tions are important for the immunogenicity of protein
molecules. A study about IFN-a2a illustrated that the
molecule became oxidized at room temperature which
in turn induce an immune response [20]. It is also dem-
onstrated by Hochuli [21] that changing to a liquid,
HSA-free formulation, and recommending storage at
4°C had reduced the immunogenicity of the product.
What is more, appropriate formulation of a protein
product is highly important, particularly with respect to
stabilization, because if this is inadequate the protein
may aggregate or denature, which increases its immuno-
genic potential [22]. Last but not least, albumin itself
was reported to result in a adverse event of rash [23].
Although there were a few studies which focused on
nab-paclitaxel regimen worldwide, there was limited
literature reported skin rash presentation among them.
Yamamoto [11] (almost all the studies included in that
review were related to nab-paclitaxel in breast cancer),
only approximate 4% patients developed skin rash
globally (Table 2). In our study, we found that the
nab-paclitaxel and cisplatin combination was associ-
ated with a higher rate of rash compared to that ofdominal wall (d).
Figure 2 Macular rash anterior tibia.
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see Table 2). Similar rash rate at 26% was reported in
another phase III study that compared nab-paclitaxel
with Cremophor-EL-containing paclitaxel in Chinese
MBC patients [10], similar to the rate reported in our
study (P > 0.05, see Table 2). On the other hand,
the skin rash rate was reported quite similar in Chinese
patients and western patients that administered
solvent-based paclitaxel [12] (P > 0.05) (See Table
2). The similarity in the skin rash rate among theTable 2 Differences in skin rash in Chinese breast cancer pati
paclitaxel
Groups, Regimen Reference No. of patients No ra
Chinese, ABX + DDP Our data 73 46
Chinese, ABX Guan et al. [21] 104 76
Chinese, PTX Guan et al. [21] 106 96
Western, PTX Seidman [22] 49 46
Western, ABX Yamamoto [20] 229 220
*Ref. is the reference of the column. The P value resulted from the comparison of tChinese population and a obviously higher skin rash
incidence in comparison with western patients sug-
gested a potential problem——a different mechanism
of action may play a role in this new agent for breast
cancer. One possible explanation is that the nab-
paclitaxel was manufactured by Abraxis BioScience
outside of China in our study. It was probable that the
albumin used in this agent, which is produced locally
in western countries, have exerted the antigenicity
effect on the Chinese population leading to the allergic
reaction.
In our study, most of the rash reaction was of non-
immediate type, defined as occurring more than one
hour after drug administration, manifested as ery-
thematous macules and infiltrated papules [24]. In a
recent phase I trial in NSCLC, 300 mg/m2 was
confirmed as the MTD and Grade 3 skin rash was one
of the DLTs [25].
As a limitation, the rate of skin rash in western pa-
tients treated with nab-paclitaxel is taken from the
literature and not from the western patients treated in
the same trial with the same regimen. The regimen
interval for nab-paclitaxel was also not in accordance as
reported which may cause the potential bias for statisical
comparison. However, the phenomenon should be paid
attention to for further study.Conclusion
A higher rate of maculo-papular rash occurred in
Chinese breast cancer patients treated with weekly
nab-paclitaxel and cisplatin. We speculate that the al-
bumin component of nab-paclitaxel might be the cause
of the skin disorder. The development of these novel
agents and their incorporation to the existing treat-
ment regimens for the management of MBC is of high
priority. Efforts should focus on decreasing the side ef-
fects while improving the quality of life of the patient.
Further improvements in our understanding of the
pathogenesis underlying the side effects are needed in
the management of these patients.ents treated with albumin-bound and conventional
sh Rash P value P vaule P value P value
27 Ref.* 0.15 <0.0001 -
28 0.15 Ref* <0.0001 -
10 <0.0001 0.001 Ref.* -
3 - - - Ref.*
9 <0.0001 0.001 - 0.49
he group and the Ref. group.
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